“Colorectal cancer does not respond to BRAF therapy alone because tumour cells adapt through other mechanisms after initial treatment,” he said. “With this triple targeted therapy, we are ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E ... enable the use of targeted treatment, according ...